Entadfi
Product Images NDC 69681-125

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Entadfi (NDC 69681-125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Veru Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Bottle Label (5 mg/5 mg)

FDA Label Image

Image Of Bottle Label (5 mg/5 mg)

FDA Label Image

Image Of Chemical Structure Of Tadalafil (Cs1)

FDA Label Image

Image Of Chemical Structure Of Finasteride (Cs2)

FDA Label Image

Image Of Mean Maximal Change In Blood Pressure (tadalafil Minus Placebo, Point Estimate With 90% Ci) In Response To Sublingual Nitroglycerin At 2 (supine Only), 4, 8, 24, 48, 72, And 96 Hours After The Last Dose Of Tadalafil 20 mg Or Placebo (Fig1)

Image Of Mean Maximal Change In Blood Pressure (tadalafil Minus Placebo, Point Estimate With 90% Ci) In Response To Sublingual Nitroglycerin At 2 (supine Only), 4, 8, 24, 48, 72, And 96 Hours After The Last Dose Of Tadalafil 20 mg Or Placebo (Fig1)
The text is presenting two tables of blood pressure readings, one for standing and the other for supine positions. The tables show the systolic and diastolic readings along with their differences. There is not enough information to determine the context or purpose of the tables.*
FDA Label Image

Image Of Doxazosin Study 1: Mean Change From Baseline In Systolic Blood Pressure (Fig2)

Image Of Doxazosin Study 1: Mean Change From Baseline In Systolic Blood Pressure (Fig2)
The text is describing a study that involves two groups of participants: one group taking Tadalafil 20mg and Doxazosin 8mg, and another group taking Placebo and Doxazosin 8mg. The study measures Supine Systolic BP (blood pressure in mmHg) over a period of time (6 to 18 hours post-dose) for both groups.*
FDA Label Image

Image Of Doxazosin Study 2 (part C): Mean Change From Time-matched Baseline In Systolic Blood Pressure (Fig3)

FDA Label Image

Image Of Mean Total Ipss Changes By Visit In Bph Patients Taking Tadalafil Together With Finasteride (Fig4)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.